CORVUS PHARMACEUTICALS, - PRIMARY ENDPOINT IS SAFETY AND TOLERABILITY; KEY EFFICACY ENDPOINT IS HISCR 50/75 AT WEEK 12

Reuters · 1d ago

Please log in to view news